Spelman, T. Et Al. 2018. A comparative effectiveness analysis applying a 3-way propensity score matching to real-world data from the MSBase registry in preparation for a cost-effectiveness model: patients switching within first-line agents or to either natalizumab or fingolimod in active relapsing-remitting multiple sclerosis. 70th Annual Meeting of the American-Academy-of-Neurology (AAN) , (Los-Angeles, Chile).

Spelman, T., Havrdova, E., Horakova, D., Trojano, M., Lugaresi, A., Izquierdo, G., ... Grammond, P.(2018). A comparative effectiveness analysis applying a 3-way propensity score matching to real-world data from the MSBase registry in preparation for a cost-effectiveness model: patients switching within first-line agents or to either natalizumab or fingolimod in active relapsing-remitting multiple sclerosis . 70th Annual Meeting of the American-Academy-of-Neurology (AAN), Los-Angeles, Chile

Spelman, Timothy Et Al. "A comparative effectiveness analysis applying a 3-way propensity score matching to real-world data from the MSBase registry in preparation for a cost-effectiveness model: patients switching within first-line agents or to either natalizumab or fingolimod in active relapsing-remitting multiple sclerosis," 70th Annual Meeting of the American-Academy-of-Neurology (AAN), Los-Angeles, Chile, 2018

Spelman, Timothy Et Al. "A comparative effectiveness analysis applying a 3-way propensity score matching to real-world data from the MSBase registry in preparation for a cost-effectiveness model: patients switching within first-line agents or to either natalizumab or fingolimod in active relapsing-remitting multiple sclerosis." 70th Annual Meeting of the American-Academy-of-Neurology (AAN) , Los-Angeles, Chile, 2018

Spelman, T. Et Al. (2018) . "A comparative effectiveness analysis applying a 3-way propensity score matching to real-world data from the MSBase registry in preparation for a cost-effectiveness model: patients switching within first-line agents or to either natalizumab or fingolimod in active relapsing-remitting multiple sclerosis." 70th Annual Meeting of the American-Academy-of-Neurology (AAN) , Los-Angeles, Chile.

@conferencepaper{conferencepaper, author={Timothy Spelman Et Al. }, title={A comparative effectiveness analysis applying a 3-way propensity score matching to real-world data from the MSBase registry in preparation for a cost-effectiveness model: patients switching within first-line agents or to either natalizumab or fingolimod in active relapsing-remitting multiple sclerosis}, congress name={70th Annual Meeting of the American-Academy-of-Neurology (AAN)}, city={Los-Angeles}, country={Chile}, year={2018}}